The DOI matches its Crossref record; 108 of the 118 references it cites were found in a registry or an index.
TP53 mutations in human cancers: origins, consequences, and clinical use.
Open accessAbstract
Somatic mutations in the TP53 gene are one of the most frequent alterations in human cancers, and germline mutations are the underlying cause of Li-Fraumeni syndrome, which predisposes to a wide spectrum of early-onset cancers. Most mutations are single-base substitutions distributed throughout the coding sequence. Their diverse types and positions may inform on the nature of mutagenic mechanisms involved in cancer etiology. TP53 mutations are also potential prognostic and predictive markers, as well as targets for pharmacological intervention. All mutations found in human cancers are compiled in the IARC TP53 Database (http://www-p53.iarc.fr/). A human TP53 knockin mouse model (Hupki mouse) provides an experimental model to study mutagenesis in the context of a human TP53 sequence. Here, we summarize current knowledge on TP53 gene variations observed in human cancers and populations, and current clinical applications derived from this knowledge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, 38-50% of human cancers carry inactivating alterations in TP53 (ref. 132 ) , 48-80% in CDKN2A 133 and 14% in CIP1 (ref. 134 ) , while 15-20% and up to 8% harbour oncogenic mutations in RAS and BRAF , respectively 135,136 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [132]
Experimental — accuracy not yet measuredIn the citing paper
“Activated p53 regulates expression of a set of anti-proliferative genes (Olivier et al., 2010; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Olivier et al., 2010
In the citing paper
“As p53 remains wild type in $50% of human cancers, 6 reactivation of p53 by small molecules is an attractive therapeutic approach.”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [6]
In the citing paper
“Tumors, which drastically deviate from these parameters, have evolved multiple mechanisms to inactivate TP53, the most prevalent of which is the emergence of TP53 missense mutations, some of which have gain-of function activities.”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Olivier, et al., 2010
In the citing paper
“In particular, missense mutations account for approximately 75% of all TP53 mutations in cancer (Hamroun, et al., 2006; Olivier, et al., 2010)”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Olivier, et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×
“The p53 DBD is made of an immunoglobulinlike b-sandwich of two antiparallel b-sheets, providing a scaffold for a flexible DNA-binding surface (Cho et al. 1994).”
Background
Flagged first, then by citations
10 of the 118 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Endogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452
Unravelling mechanisms of p53-mediated tumour suppression
Bieging-Rolett, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3711 · Cited by 1,454
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,145
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 949
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.86 · Cited by 867
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 876
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
González-Pérez, A., & López-Bigas, N. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.004 · Cited by 772
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 805
Mutant p53 Gain-of-Function in CancerPreprint
Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 778
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 771
A Compendium of Mutational Signatures of Environmental Agents
Kucab, J. E., Zou, X., Morganella, S., Joel, M., Nanda, A. S., Nagy, E., Gomez, C., Degasperi, A., Harris, R., Jackson, S. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.001 · Cited by 660
MEG3 noncoding RNA: a tumor suppressor
Zhou, Y., Zhang, X., & Klibanski, A. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0008 · Cited by 724
Context is everything: aneuploidy in cancer
Ben‐David, U., & Amon, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0171-x · Cited by 683
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 676
Somatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Exposure to polycyclic aromatic hydrocarbons with special focus on cancer
Rengarajan, T., Rajendran, P., Nandakumar, N., Boopathy, L. K., Palaniswami, R., & Nishigaki, I. (2015) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(15)30003-4 · Cited by 603
Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Chamoli, A., Gosavi, A., Shirwadkar, U. P., Wangdale, K. V., Behera, S. K., Kurrey, N. K., Kalia, K., & Mandoli, A. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105451 · Cited by 616
Major apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Yandım, M. K., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 605
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
Shain, A. H., & Pollack, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055119 · Cited by 601
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 594
Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis
Hatakeyama, M. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.008 · Cited by 557
Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 571
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Human Organoids: Tools for Understanding Biology and Treating Diseases
Schutgens, F., & Clevers, H. C. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032611 · Cited by 530
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.81 · Cited by 471
p53 Research: The Past Thirty Years and the Next Thirty YearsPreprint
Lane, D. P., & Levine, A. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 469
The diversified role of mitochondria in ferroptosis in cancer
Liu, Y., Lu, S.-P., Wu, L., Yang, L., Wang, J., & Wang, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06045-y · Cited by 486
Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., & Attardi, L. D. (2013) · Genes & Development · doi:10.1101/gad.212282.112 · Cited by 443
Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M. K., Kolstad, A., Pedersen, L. B., Montano‐Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779736 · Cited by 414
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 404
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P. I., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 391
Brady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 400
The Significance of Mitochondrial Dysfunction in Cancer
Luo, Y., Ma, J., & Lu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165598 · Cited by 380
The molecular pathogenesis of head and neck squamous cell carcinoma
Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 372
Maitra, A., Biswas, N. K., Amin, K. M., Kowtal, P., Kumar, S., Das, S. K., Sarin, R., Majumder, P. P., Bagchi, I., Bairagya, B. B., et al. (2013) · Nature Communications · doi:10.1038/ncomms3873 · Cited by 362
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 355
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E. D., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 341
Protein Folding and Mechanisms of Proteostasis
Díaz‐Villanueva, J. F., Díaz-Molina, R. J., & García‐González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 354
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 345
p53 Acetylation: Regulation and Consequences
Reed, S. M., & Quelle, D. E. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 344
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Song, T. L., Nairismägi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., Pang, W.-L., Kizhakeyil, A., Wijaya, G.-C., Huang, D.-C., et al. (2018) · Blood · doi:10.1182/blood-2018-01-829424 · Cited by 326
Allele-Specific p53 Mutant Reactivation
Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 321
Molecular biomarkers in acute myeloid leukemia
Prada‐Arismendy, J., Arroyave-Ospina, J. C., & Röthlisberger, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 316
Using Epidemiology and Genomics to Understand Osteosarcoma Etiology
Savage, S. A., & Mirabello, L. J. (2011) · Sarcoma · doi:10.1155/2011/548151 · Cited by 309
Mutational drivers of cancer cell migration and invasion
Novikov, N. M., Zolotareva, S. Y., Gautreau, A. M., & Denisov, E. V. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01149-0 · Cited by 327
Takahashi‐Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0339-5 · Cited by 318
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 302
Oxidatively induced DNA damage: Mechanisms, repair and disease
Dizdaroğlu, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.016 · Cited by 504
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 301
Kotler, E., Shani, O., Goldfeld, G., Lotan‐Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 292
Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living
Heitzer, E., Auinger, L., & Speicher, M. R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.012 · Cited by 290
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Bom, A. P. D. A., Rangel, L. P., da Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A. C. A., Gava, L. M., Ramos, C. H. I., Tiroli‐Cepeda, A. O., Stumbo, A. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340638 · Cited by 284
Nakayama, M., & Oshima, M. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy075 · Cited by 294
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K. N., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 301
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 286
Golding, B., Luu, A. K., Jones, R. A., & Viloria‐Petit, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0810-4 · Cited by 285
NOD-Like Receptors: Master Regulators of Inflammation and Cancer
Saxena, M., & Yeretssian, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00327 · Cited by 282
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 274
Alternative mechanisms of miR-34a regulation in cancer
Slabáková, E., Čulig, Z., Remšík, J., & Souček, K. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.495 · Cited by 275
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 267
Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G. M., Jabbour, E. J., Konopleva, M. Y., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261
Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M., Spector, L. G., Morton, L. M., Karyadi, D., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0197 · Cited by 243
Oxidatively induced DNA damage and its repair in cancer
Dizdaroğlu, M. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.002 · Cited by 264
Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangementsPreprint
Zhang, C., Leibowitz, M. L., & Pellman, D. S. (2013) · Genes & Development · doi:10.1101/gad.229559.113 · Cited by 258
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Chen, S., Wu, J., Liang, Y., Tang, Y., Song, H., Wu, L., Xing, Y., Yan, N., Li, Y., Wang, Z., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.013 · Cited by 250
Jin, M. H., & Oh, D. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.002 · Cited by 260
Somatic TP53 Mutations in the Era of Genome SequencingPreprint
Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256
Self-citationALTernative Telomere Maintenance and Cancer
Dilley, R. L., & Greenberg, R. A. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.007 · Cited by 251
Shieh, Y., Eklund, M., Madlensky, L., Sawyer, S. D., Thompson, C. K., Fiscalini, A. S., Ziv, E., Veer, L. J. V., Esserman, L. J., & Tice, J. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw290 · Cited by 243
Yoshida, G. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0436-9 · Cited by 239
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.171 · Cited by 232
Francies, F. Z., Hull, R., Khanyile, R., & Dlamini, Z. (2020) · PubMed Central · Cited by 228
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 226
The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis
Potapova, T., & Gorbsky, G. J. (2017) · Biology · doi:10.3390/biology6010012 · Cited by 238
Genetic Markers in Lung Cancer Diagnosis: A Review
Wadowska, K., Bil‐Lula, I., Trembecki, Ł., & Śliwińska‐Mossoń, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134569 · Cited by 228
The genome as a record of environmental exposure
Nik‐Zainal, S., Kucab, J. E., Morganella, S., Głodzik, D., Alexandrov, L. B., Arlt, V. M., Weninger, A., Hollstein, M. C., Stratton, M. R., & Phillips, D. H. (2015) · Mutagenesis · doi:10.1093/mutage/gev073 · Cited by 209
Self-citationDual Role of Reactive Oxygen Species and their Application in Cancer Therapy
Huang, R., Chen, H., Liang, J., Li, Y., Yang, J., Luo, C., Tang, Y., Ding, Y., Liu, X., Yuan, Q., et al. (2021) · Journal of Cancer · doi:10.7150/jca.54699 · Cited by 228
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Cole, A. J., Dwight, T., Gill, A. J., Dickson, K.-A., Zhu, Y., Clarkson, A., Gard, G. B., Maidens, J., Valmadre, S., Clifton-Bligh, R. J., et al. (2016) · Scientific Reports · doi:10.1038/srep26191 · Cited by 208
Neat1 is a p53-inducible lincRNA essential for transformation suppressionPreprint
Mello, S. S., Sinow, C., Raj, N., Mazur, P. K., Bieging-Rolett, K. T., Brož, D. K., Conklin, J. F., Vogel, H. S., Wood, L. D., Sage, J., et al. (2017) · Genes & Development · doi:10.1101/gad.284661.116 · Cited by 209
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan, Z., Ding, Y., Kim, J.-H., Jung, H. H., Chung, W., Lal, S., Cho, S., Fernandez-Banet, J., Lee, S. K., Kim, S. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04129-4 · Cited by 200
Li, W., Li, F., Zhang, X., Lin, H., & Xu, C. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 211
Cancer as a Metabolic Disorder
Gyamfi, J., Kim, J., & Choi, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031155 · Cited by 206
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
El-Sayes, N., Vito, A., & Mossman, K. L. (2021) · Cancers · doi:10.3390/cancers13040806 · Cited by 208
Mutant p53: it’s not all one and the same
Kennedy, M. C., & Lowe, S. W. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00989-y · Cited by 211
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 198
Uversky, V. N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111874 · Cited by 197
Expanding PROTACtable genome universe of E3 ligases
Liu, Y., Yang, J., Wang, T., Luo, M., Chen, Y., Chen, C., Ronai, Z. A., Zhou, Y., Ruppin, E., & Han, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42233-2 · Cited by 210
Mining cancer methylomes: prospects and challenges
Stirzaker, C., Taberlay, P. C., Statham, A. L., & Clark, S. J. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.11.004 · Cited by 202
VanderLaan, P. A., Rangachari, D., Mockus, S. M., Spotlow, V., Reddi, H. V., Malcolm, J., Huberman, M. S., Joseph, L. J., Kobayashi, S. S., & Costa, D. B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.011 · Cited by 190
Dai, X., Zhang, J., Arfuso, F., Chinnathambi, A., Zayed, M., Alharbi, S. A., Kumar, A. P., Ahn, K. S., & Sethi, G. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215579167 · Cited by 193
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update
Liu, M., Jiang, L., & Guan, X. (2014) · Protein & Cell · doi:10.1007/s13238-014-0065-9 · Cited by 183
Metadata
- Authors
- Olivier, M., Hollstein, M., & Hainaut, P.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- University of Leeds (GB)
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-11-11
- Volume
- 2
- Issue
- 1
- Pages
- a001008-a001008
- ISSN
- 1943-0264 (ISSN-L)
- PMC
- PMC2827900
- OpenAlex
- W2129769331
- Cited by
- 2,199
- References
- 118
- Citations by year
- 2026: 136 · 2025: 174 · 2024: 233 · 2023: 229 · 2022: 222 · 2021: 178 · 2020: 174 · 2019: 112 · 2018: 139 · 2017: 131 · 2016: 101 · 2015: 97 · 2014: 88 · 2013: 61 · 2012: 72
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53 mutation, somatic mutations, germline TP53 mutation, Li-Fraumeni syndrome, cancer susceptibility, mutagenesis mechanism, prognostic factors, predictive biomarkers, therapeutic target, cancer etiology
- MeSH terms
- Animals, Carcinogens, Humans, Mice, Transgenic, Models, Biological, Mutation, Neoplasms, Prognosis, Gene Expression Regulation, Neoplastic, Genes, p53, Mutagenesis, CpG Islands, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
